Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma

Haematologica. 2023 May 1;108(5):1412-1416. doi: 10.3324/haematol.2022.282031.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cell- and Tissue-Based Therapy
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Mantle-Cell* / pathology
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen
  • venetoclax
  • pirtobrutinib

Grants and funding

Funding: This work was supported by an SRA grant from LOXO Oncology at Lilly. LOXO Oncology at Lilly provided the pirtobrutinib.